Assembly Biosciences Inc (ASMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.49 Million) by net assets ($305.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Assembly Biosciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Assembly Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency. Explore ASMB operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
-1.556x |
|
Zhongyan Technology Co Ltd
SHE:003001
|
0.050x |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
0.053x |
|
Shaanxi Xinghua Chemistry Co Ltd
SHE:002109
|
-0.015x |
|
Bhakti Multi Artha Pt
JK:BHAT
|
-0.003x |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
0.061x |
|
PlayAGS Inc
NYSE:AGS
|
0.226x |
|
Shanghai Metersbonwe Fashion&Accessories Co Ltd
SHE:002269
|
-0.519x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2025. View current stock price of Assembly Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $206.75 Million | $-41.09 Million | -0.199x | +87.03% |
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more